Table 1.
Baseline characteristics
| Characteristics | Number (%) |
|---|---|
| Number of patients | 85 |
| Follow-up (months)a | 38.6 (29.4–60.1) |
| Age (years)a | 56 (44–66) |
| Breast tumor size (cm)a | 1.7 (1.15–2.9) |
| Stage at diagnosis | |
| I | 49 (57.7) |
| II | 29 (34.1) |
| III | 7 (8.2) |
| Histologic subtypes | |
| Ductal | 67 (78.8) |
| Lobular | 12 (14.1) |
| Ductolobular | 5 (5.9) |
| Other | 1 (1.2) |
| Histologic grade | |
| 1 | 19 (22.4) |
| 2 | 45 (52.9) |
| 3 | 21 (24.7) |
| Hormonal receptors | |
| Estrogen receptora | 67 (43–88) |
| Progesterone receptora | 50 (5–70) |
| Ki67 (n:76)a | 9 (5–16) |
| High (>20) | 11 (14.5) |
| Lymphovascular invasion | 51 (59.3) |
| Tumor phenotype | |
| Luminal A | 50 (58.8) |
| Luminal B | 20 (23.5) |
| Luminal HER2 | 6 (7.1) |
| HER2 | 4 (4.7) |
| Triple negative | 5 (5.9) |
| Lymph nodes metastasis | 32 (37.6) |
| Postsurgical treatment | |
| Hormonotherapy | 70 (82.4) |
| Chemotherapy | 47 (55.3) |
Note:
a
Median number (interquartile range).